Catalio Capital Management, LP
Position in RARE — Ultragenyx Pharmaceutical Inc.
CIK 1958125
NEW YORK, NY
Position in RARE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$10,559,654
-$7,264,543 QoQ
Shares Held
316,252
-62.8% QoQ
Ownership
0.321%
of shares outstanding
% of Portfolio
1.98%
of 13F equity value
Holder Rank
#56
of 311 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RARE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Catalio Capital Management, LP holds $385,997,200 across 31 Biotechnology names. RARE ranks #14 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AVLN |
Avalyn Pharma Inc.
|
1,675,830 | $55,168,323 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
455,041 | $33,891,453 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
1,215,698 | $26,575,158 | |
| 4 | DFTX |
Definium Therapeutics, Inc.
|
562,672 | $26,468,090 | |
| 5 | PBLS |
Parabilis Medicines, Inc.
|
824,043 | $22,554,056 | |
| 6 | INCY |
Incyte Corp
|
191,627 | $21,722,836 | |
| 7 | SEPN |
Septerna, Inc.
|
536,152 | $17,955,730 | |
| 8 | MLYS |
Mineralys Therapeutics, Inc.
|
648,722 | $17,502,519 |
All Filings in RARE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,559,654 | 316,252 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $17,824,197 | 850,797 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,738,650 | 162,550 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $8,761,160 | 291,262 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,759,296 | 213,402 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||